Department of General Surgery, School of Medicine, University of Yuzuncu Yil, Van, Turkey.
Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2923-8.
Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients.
Pre-treatment serum levels of TATI in patients with gastric cancer and healthy controls were analyzed by a specific enzyme-linked immunosorbent assay (ELISA).
Statistically significant differences were found in serum TATI levels between patients with gastric cancer and healthy controls (p < 0.0001). There was a significant relationship between the serum levels of TATI and clinicopathological parameters. However, serum levels of TATI were significantly higher in patients with an advanced T stage (T3) (p < 0.001), lymph node metastasis (p < 0.001) and an advanced TNM stage (stage III or IV; p < 0.001).
Our study suggests that TATI may be used to identify potentially high-risk groups of upper gastric carcinoma. Elevated level of TATI was associated with progressive disease or advanced stage.
肿瘤相关胰蛋白酶抑制剂（TATI）与胰蛋白酶原一起在肿瘤中表达。我们研究了术前胃癌患者血清 TATI 水平与临床病理的关系及其意义。
采用特定的酶联免疫吸附试验（ELISA）分析胃癌患者和健康对照者的术前血清 TATI 水平。
胃癌患者与健康对照组血清 TATI 水平存在显著差异（p<0.0001）。血清 TATI 水平与临床病理参数之间存在显著关系。然而，T 分期（T3）较高（p<0.001）、淋巴结转移（p<0.001）和更晚期的 TNM 分期（III 期或 IV 期；p<0.001）的患者血清 TATI 水平显著升高。
本研究表明，TATI 可用于鉴定上消化道癌的高危人群。TATI 水平升高与疾病进展或晚期有关。
